Recombinant KRT8 antibody (full length)

Catalog No. ABIN7878514

The Mouse Monoclonal anti-KRT8 antibody (Clone rKRT8-6471) (ABIN7878514) specifically detects KRT8 in WB and IHC (p). The antibody is reactive with Human samples.

Quick Overview for Recombinant KRT8 antibody (full length) (ABIN7878514)

Target: KRT8 (Keratin 8 (KRT8))

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This KRT8 antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Grade: Carrier-free

Clone: RKRT8-6471

Product Details anti-KRT8 Antibody

Binding Specificity: full length

Purpose: Recombinant KRT8 Antibody / Cytokeratin 8 (azide and preservative free)

Purification: Protein A/G affinity

Immunogen: Recombinant full-length human KRT8 protein was used as the immunogen for the recombinant KRT8 antibody.

Isotype: IgG2a, kappa

Application Details

Application Notes: Optimal dilution of the recombinant KRT8 antibody should be determined by the researcher.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Preservative: Azide free

Storage: -20 °C

Storage Comment: Aliquot the recombinant KRT8 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Target Details for KRT8

Target: KRT8 (Keratin 8 (KRT8))

Alternative Name: KRT8

Background: Cytokeratin 8 (also called CK8, Keratin 8 and KRT8) belongs to the type II (or B or basic) subfamily of high molecular weight cytokeratins and exists in combination with cytokeratin 18 (CK18). CK8 is primarily found in the non-squamous epithelia and is present in majority of adenocarcinomas and ductal carcinomas. It is absent in squamous cell carcinomas. Hepatocellular carcinomas are defined by the use of antibodies that recognize only cytokeratin 8 and 18. CK8 exists on several types of normal and neoplastic epithelia, including many ductal and glandular epithelia such as colon, stomach, small intestine, trachea, and esophagus as well as in transitional epithelium. Anti-CK8 does not react with skeletal muscle or nerve cells. Epithelioid sarcoma, chordoma, and adamantinoma show strong positivity corresponding to that of simple epithelia (with antibodies against CK8, CK18 and CK19). Anti-CK8 is useful for the differentiation of lobular (ring-like, perinuclear) from ductal (peripheral-predominant) carcinoma of the breast.

UniProt: P05787